Conference Coverage

Autoimmune-mediated gut dysmotility puts patients at risk for bacterial overgrowth

Publish date: October 4, 2016

 

On Twitter @karioakes

Pages

Recommended Reading

Biosimilar infliximab gains FDA Advisory Committee endorsement
MDedge Rheumatology
Inflectra becomes first FDA-approved biosimilar for inflammatory diseases
MDedge Rheumatology
Make informed treatment decisions about biosimilars
MDedge Rheumatology
Immunosuppressive regimens did not affect risk of cancer recurrence in meta-analysis
MDedge Rheumatology
Study: TNF inhibitors improve extraintestinal IBD manifestations
MDedge Rheumatology
Updated Behçet’s disease recommendations expand biologic treatment
MDedge Rheumatology
European experience: Biosimilar infliximab works as well as Remicade for IBD
MDedge Rheumatology
FDA advisory panel unanimously backs biosimilars for Humira, Enbrel
MDedge Rheumatology
Anticipate, treat GI issues in scleroderma
MDedge Rheumatology
FDA approves biosimilar adalimumab
MDedge Rheumatology